ASH 2018 | Renal response to carfilzomib vs. bortezomib in R/R MM in the real world
VJHemOnc is committed to improving our service to you
Thanks for your feedback, this will help us improve our content for you!
In clinical trials, the proteasome inhibitors carfilzomib (K) and bortezomib (V) have demonstrated efficacy in relapsed/refractory multiple myeloma (MM) patients with renal impairment (RI). Noopur Raje, MD, of Massachusetts General Hospital, Boston, MA, introduces a study aiming to tackle the lack of real world data in R/R MM patients treated with K plus dexamethasone (Kd) and V plus dexamethasone (Vd) in clinical practice. Speaking from the American Society of Hematology (ASH) 2018 Annual Meeting and Exposition in San Diego, CA, Dr Raje reveals that patients treated with Kd had higher rates of overall and complete renal response, and were more likely to have a renal response, compared with those treated with Vd.
Get great new content delivered to your inboxSign up